logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASCO 2020 – Are anthracyclines necessary in the neoadjuvant treatment of HER2-positive breast cancers?

No survival benefit was shown in the long-term when using anthracyclines in the presence of dual HER2-blockade for stage II-III breast cancers